Torrent Pharma

Strong domestic growth, a chronic-heavy portfolio, JB Pharma integration benefits and gains in semaglutide are expected to support Torrent Pharma's near-term performance

Torrent Pharmaceuticals on Tuesday reported a 3.3 per cent increase in consolidated net profit at Rs 566 crore in the first quarter ended June 30, 2026. The company had posted a consolidated net profit of Rs 548 crore in the corresponding quarter last fiscal, Torrent Pharmaceuticals Ltd said in a regulatory filing. Consolidated total revenue from operations in the first quarter stood at Rs 4,921 crore as against Rs 3,178 crore in the year-ago period, it added. Total expenses in the quarter under review were higher at Rs 4,155 crore as compared to Rs 2,403 crore in the same quarter a year ago, the company said. India revenues were at Rs 2,157 crore in the first quarter, up 19 per cent from the year-ago period, and US revenues were also at Rs 418 crore, up 36 per cent, it added. Brazil revenues stood at Rs 277 crore, up 27 per cent, and the same for Germany was at Rs 318 crore, up 3 per cent year-on-year, the company said.

The BSE Healthcare hit a new high of 51,108 on Friday, rallying 3.7% in July. The index has surged 22% since April 2026.

Pharma stock rally: Orchid Pharma, Hikal, Unichem Labs, IOL Chemicals, SPARC, RPG Life Sciences and Acutaas Chemicals surged up to 13% in Wednesday's trade.

Stocks to watch today: Power Grid, Sterlite Technologies, ZEN Technologies, TVS Motor Company, Varun Beverages, Torrent Pharma, Cochin Shipyard, Titan, Trent, among others, will be in focus today

The stock delivered higher returns than the benchmark Nifty Pharma over the past year

Torrent Pharma's revenue from operations rose 42 per cent Y-o-Y to ₹4,197 crore in Q4FY26 from ₹2,959 crore in Q4FY25

Torrent Pharmaceuticals Ltd on Friday reported a 27 per cent decline in profit after tax to Rs 364 crore in the fourth quarter ended March 31, 2026, impacted by exceptional items outgo. The company had posted a net profit of Rs 498 crore in the corresponding period of the preceding fiscal, Torrent Pharmaceuticals said in a statement. Total revenue from operations in the fourth quarter of FY26 stood at Rs 4,197 crore as against Rs 2,959 crore in the year-ago period, it added. The company had exceptional items outgo of Rs 66 crore in the quarter, as per the regulatory filing. The board has recommended a final dividend of Rs 9 per equity share of a face value of Rs 5 each. The pharma company's India business revenue stood at Rs 2,215 crore, up 43 per cent, in the quarter, while the Brazil revenue came in at Rs 455 crore, up by 30 per cent. Revenue from the US business stood at Rs 396 crore, up 31 per cent year-on-year, Torrent Pharma said. For FY26, net profit increased to Rs 2,138

Torrent Pharma's Q4 profit dropped 22% as JB Pharma integration costs pushed up expenses, despite strong growth in semaglutide-led revenues

Torrent Group has entered the diagnostics sector with a 100,000 sq ft national reference lab in Navi Mumbai, marking a long-term push into high-end, specialised testing amid industry consolidation

Stocks to Watch today, Feb 16: From Ola Electric to Inox Green Energy, here are few stocks that will be on investors' radar

Ahmedabad-based drugmaker reports Rs 635 crore Q3 profit on strong India, Brazil and US growth; revenues rise 17.6% to Rs 3,303 crore

Torrent Pharma Q3 revenue from operations increased 17.7 per cent year-on-year (Y-o-Y) to ₹3,251 crore from ₹2,762 crore in Q3FY25

Torrent Pharmaceuticals said the tenure of the instruments, along with the date of allotment and final maturity, will be determined at the time of issuance of NCDs

Antique resumed coverage on Torrent Pharma with a 'buy' rating, Cipla and Dr Reddy's Lab with 'hold' ratings, and Concord Biotech with a 'buy' rating

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

Led by the India business and rest-of-the-world markets, the company reported a robust 14.3 per cent year-on-year (Y-o-Y) growth in revenues

Torrent Pharmaceuticals posted a 16% rise in Q2FY26 profit to Rs 591 crore, with double-digit growth across India, the US, and Brazil driving revenue higher.

Fair trade regulator CCI on Tuesday cleared Torrent Pharmaceuticals Ltd's proposed acquisition of a stake in JB Chemicals and Pharmaceuticals, subject to voluntary modifications offered by the companies. The development came after Torrent Pharmaceuticals in June this year announced the acquisition of a majority stake in JB Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. "The proposed combination relates to the acquisition of shareholding by Torrent Pharmaceuticals Ltd (acquirer) in JB Chemicals & Pharmaceuticals Ltd (target) and the subsequent amalgamation of the target with the acquirer," the regulator said in a release. After the completion of the deal, Torrent Pharmaceuticals will become India's second most valued pharma company. "The Commission approved the proposed combination subject to compliance with voluntary modifications offered by the parties (Torrent Pharmaceuticals Ltd and JB Chemicals & Pharmaceuticals Ltd)," it added. Torrent Pharmaceuticals is the ...

Analysts are optimistic on Torrent Pharma's growth after a solid Q1 FY26 report, with strong performance in Brazil and US generics despite currency volatility and German challenges